Jacobs Levy Equity Management’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,650
| Closed | -$799K | – | 1013 |
|
|
2021
Q3 | $799K | Buy |
3,650
+360
| +11% | +$78.8K | 0.01% | 798 |
|
|
2021
Q2 | $763K | Sell |
3,290
-1,075
| -25% | -$249K | 0.01% | 797 |
|
|
2021
Q1 | $1.31M | Buy |
4,365
+1,181
| +37% | +$356K | 0.01% | 679 |
|
|
2020
Q4 | $1.2M | Buy |
3,184
+881
| +38% | +$331K | 0.01% | 678 |
|
|
2020
Q3 | $707K | Sell |
2,303
-588
| -20% | -$181K | 0.01% | 723 |
|
|
2020
Q2 | $1.09M | Buy |
2,891
+2,035
| +238% | +$765K | 0.01% | 655 |
|
|
2020
Q1 | $195K | Buy |
856
+302
| +55% | +$68.8K | ﹤0.01% | 891 |
|
|
2019
Q4 | $293K | Buy |
+554
| New | +$293K | ﹤0.01% | 858 |
|
|
2017
Q1 | – | Sell |
-192
| Closed | -$117K | – | 946 |
|
|
2016
Q4 | $117K | Sell |
192
-74
| -28% | -$45.1K | ﹤0.01% | 886 |
|
|
2016
Q3 | $190K | Sell |
266
-21
| -7% | -$15K | ﹤0.01% | 917 |
|
|
2016
Q2 | $208K | Buy |
287
+14
| +5% | +$10.1K | ﹤0.01% | 1005 |
|
|
2016
Q1 | $162K | Sell |
273
-6
| -2% | -$3.56K | ﹤0.01% | 996 |
|
|
2015
Q4 | $160K | Buy |
279
+103
| +59% | +$59.1K | ﹤0.01% | 712 |
|
|
2015
Q3 | $99K | Sell |
176
-121
| -41% | -$68.1K | ﹤0.01% | 761 |
|
|
2015
Q2 | $236K | Buy |
+297
| New | +$236K | ﹤0.01% | 700 |
|